Evidence map›Paper›PMID 40689455›Full record

ArticlePsychological medicine2025

Premorbid school performance trajectories in patients with treatment-resistant schizophrenia prescribed clozapine in the public health system in Chile: a case-control study, 2007-2020.

Jose Conejeros-Pavez, Javiera Vasquez, Camila Diaz, Cristian Mena, Juan Undurraga, Alfonso Gonzalez-Valderrama, Susana Claro, Eduardo A Undurraga, Nicolas A Crossley

Abstract read
In one paragraph

Article in Psychological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jose Conejeros-PavezSchool of Government, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.
Javiera VasquezSchool of Government, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.
Camila DiazPharmacovigilance Program, Dr. José Horwitz Barak Psychiatric Institute, Santiago, Chile.
Cristian MenaEarly Intervention Program, Dr. José Horwitz Barak Psychiatric Institute, Santiago, Chile.
Juan UndurragaDepartment of Neurology and Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
Alfonso Gonzalez-ValderramaEarly Intervention Program, Dr. José Horwitz Barak Psychiatric Institute, Santiago, Chile.
Susana ClaroSchool of Government, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.
Eduardo A UndurragaSchool of Government, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-4425-1253
Nicolas A CrossleyDepartment of Psychiatry, School of Medicine, https://ror.org/04teye511Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-3060-656X

Funding

Agencia Nacional de Investigación y Desarrollo 1240426Agencia Nacional de Investigación y Desarrollo 1242022Agencia Nacional de Investigación y Desarrollo FONDAP 1522A0005
6 · The paper itself

Abstract

backgroundThe premorbid phase of treatment-resistant schizophrenia (TRS) may reveal underlying mechanisms and inform early interventions. According to the neurodevelopmental hypothesis, treatment resistance may be linked to pronounced developmental impairments. We examined school grades and attendance trajectories in children who later developed TRS.

methodsThis case-control study analyzed school grade point average and attendance among all individuals born after 1990 and started on clozapine in Chile's public health system as a proxy for TRS. Control groups included children later diagnosed with treatment-responsive schizophrenia, bipolar disorder, and unaffected classmates. Linear mixed models accounted for individual and school-level confounders.

resultsWe included 1072 children (9929 observations, 29.3% female) subsequently diagnosed with TRS, 323 (2802 observations, 25.7% female) with schizophrenia, 175 (1784 observations, 53.8% female) bipolar disorder, and 273,260 (533,335 observations, 47% female) unaffected classmates. Children who later developed TRS had worse grades across levels than their classmates (-0.26 SD [-0.2, -0.4]), but not treatment-responsive schizophrenia. All severe mental illness groups showed grade declines in later school levels, with TRS showing steeper linear decline than treatment-responsive schizophrenia (

conclusionsTRS may stem from a more aggressive pathological process or pronounced late-maturation abnormality, rather than an early premorbid impairment, suggesting an intervention target.

Indexed as

Academic PerformanceAntipsychotic AgentsBipolar DisorderClozapineSchizophreniaSchizophrenia, Treatment-ResistantAdolescentCase-Control StudiesChildChileFemaleHumansMaleAntipsychotic AgentsClozapineglobal healthlong-term outcomespremorbid academic achievementpsychiatrytreatment-resistant schizophrenia

Identifiers

PMID40689455
PMCPMC12315655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.